GLP-1 Side Effects: What the Trials Report

GLP-1 medications are effective, but they’re not free of cost — and the honest way to weigh any drug is to look at what the controlled trials actually documented rather than anecdotes in either direction. These compounds have been studied in large randomized trials, so the side-effect picture is reasonably well characterized.

The gastrointestinal story dominates

The most common side effects are gastrointestinal, and they show up consistently across the major trials. SURMOUNT-4, a tirzepatide trial published in JAMA in 2023, gives concrete numbers. During its 36-week open-label tirzepatide lead-in period, the most frequent gastrointestinal events were:

Adverse event	Frequency (lead-in)
Nausea	35.5%
Diarrhea	21.1%
Constipation	20.7%
Vomiting	16.3%

The trial reported that most of these events were mild to moderate in severity, and that the rate of new events decreased over time during the lead-in — consistent with the pattern most people describe. They cluster around dose escalation, which is exactly why these drugs are titrated up slowly.

The honest framing: for most people the side effects are gastrointestinal, dose-related, and tend to ease over time — not trivial, but usually navigable. In SURMOUNT-4, 7.0% of participants discontinued during the lead-in due to adverse events, mainly gastrointestinal ones.

Beyond the common: what the labels flag

The trials and labeling also note less common but more serious considerations. Gallbladder problems can occur, partly related to rapid weight loss itself. Pancreatitis is listed as a risk and warrants prompt evaluation if severe abdominal pain develops. There are thyroid-tumor warnings carried over from rodent studies, which is why these drugs carry contraindications in people with certain personal or family thyroid-cancer histories — though the human relevance remains debated.

A note on dehydration

Persistent vomiting or diarrhea can lead to dehydration, which in turn can stress the kidneys. This is one reason staying hydrated and not pushing through severe symptoms matters.

The takeaway

The controlled data paints a coherent picture: GLP-1 side effects are mostly gastrointestinal, concentrated during dose escalation, and often ease over time, with a smaller set of rarer but serious risks that the labeling flags clearly. In a trial like SURMOUNT-4, nausea topped the list at about a third of participants, and roughly 7% stopped during the lead-in over adverse events. None of this argues against the drugs for appropriate candidates — it argues for sensible titration, attention to warning-sign symptoms, and a clinician in the loop. Effective and side-effect-free were never going to be the same thing.

Sources

• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2023)